* ProKidney Corp PROK.OQ PROK.O is expected to report
results on August 7 (estimated).
*
* Refinitiv's mean analyst estimate for ProKidney Corp is
for a
loss of 39 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ProKidney
Corp is
$15, above its last closing price of $12.94.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.25 -0.39 -0.16 Beat 59.1
Dec. 31 2023 -0.24 -0.25 -0.11 Beat 55.1
Sep. 30 2022 -0.06 -0.24 -0.13 Beat 44.8
This summary was machine generated August 5 at 02:06 GMT. All
figures in US dollars unless otherwise stated